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xABSTRACT
ERK negatively regulates TLR2 induced transcription of
TNFα, IL-6, iNOS, Cox2, and IL1β in Bone Marrow
Derived Macrophages.
Chulhan Kim
Department of Integrated OMICs for Biomedical Science
The Graduate School
Yonsei University
Extracellular signal-regulated kinase (ERK) was recently identified as a type of
mitogen-activated protein kinase involved in Toll-like Receptor (TLR) downstream
signaling and its corresponding cytokine production in bone marrow derived
macrophages. Previous papers focused on the correlation between TLR4 induced
transcription and ERK when introduced to Lipopolysaccharide (LPS). Here, I
evaluate the relationship between ERK and TLR2 induced transcription when
Pam3CSK4 is applied. Specifically, I assessed ERK dependent regulation of
pro-inflammatory cytokines such as TNFα, IL-6, iNOS, Cox2, and IL1β in order
to illustrate the pathway in which ERK negatively regulates TLR2 induced
transcription. Since no direct inhibitor of ERK exists, I used a well-defined
inhibitor (U0126) of Mitogen-activated protein kinase kinase (MEK1/2), an
upstream factor known to directly regulate ERK, to test ERK-dependent negative
regulation. In order to detect protein and mRNA level of the cytokines, I used
Western Blotting and quantitative Real-time Reverse Transcription Polymerase
Chain Reaction(qRT-PCR), respectively. Furthermore, to locate the point in which
xi
negative regulation of TLR2 downstream transcription by ERK occurs, I evaluated
potential pathways suggested by previous studies involving MEK1/2 and
phosphorylated Signal Transducers and Activators of Transcription (p-STAT)
using Western Blotting. Results showed that activation by Pam3CSK4 took a
distinct pathway from LPS, leading to diagnosis of other potential pathways
involving phosphorylation of p38, JNK, IκBα, and CREB. In addition, I tested
macrophage-like cell lines: J774A.1, Immortalized bone marrow derived macrophage
(iBMDM), and Raw264.7 to create a MEK1/2 knockout cell line using the
CRISPR-CAS9 system for substitution of in vivo experimentation with knockout
mice. In final, to confirm that the negative regulation effect is TLR2 specific,
TLR2 specific ligands: Pam3CSK4 and Lipoteichoic Acid (LTA) are contrasted
with ligands of TLR3, TLR4, and TLR9. Collectively, these data suggest that ERK
negatively regulates TLR2-induced transcription of pro-inflammatory cytokines:
TNFα, IL-6, iNOS, Cox2, and IL1β. These findings may contribute in the
development of drugs that modulate TLR activity to treat inflammatory diseases
and cancer.
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1Introduction
There are ten known types of human TLRs. These ten types can be categorized
into two main groups. (Doyle, O’Neil et al. 2006) The first group: TLR1, TLR2,
TLR4, TLR5, and TLR6 triggers anti-bacterial responses (Kumar et al. 2009).
TLR4, the dominantly analyzed TLR, senses LPS, a component of the
gram-negative bacteria cell wall (Akira, Uematsu et al. 2006). TLR2 works
synergistically with TLR1, TLR5, and TLR6 to verify distinct pathogen-associated
molecular patterns (PAMPs) (Kumar et al. 2009). To be more specific, TLR2
cooperates with TLR1, TLR5, and TLR6 to recognize triacylated lipop eptides,
bacterial flagellin, and diacylated lipopeptides, respectively (Akira, Uematsu et al.
2006). Moreover, TLR2 also senses numerous fungal and protozoal products (Akira,
Uematsu et al. 2006). The second group: TLR3, TLR7, TLR8, and TLR9 initiates
anti-viral reactions (Kumar et al. 2009). TLR3 acknowledges double stranded
RNA, TLR7 and TLR8 recognize single stranded RNA, and TLR9 distinguishes
CpG motifs, which exist in both virus and bacteria (Kumar et al. 2009). In short,
here I analyze the downstream signaling of two TLRs: TLR4 and TLR2 from the
anti-bacterial group, that is divergent from the remaining eight types of TLRs.
TLR4 stimulation is known to activate numerous signaling pathways including
two pathways involving mitogen-activated protein kinases (MAPKs) and Janus
kinase(JAK)-STAT (Xiaoyu Hu et al. 2007; Kaisho and Akira 2006). MAPKs,
include p38 kinase, c-Jun NH(2)-terminal kinase (JNK), and ERK (Kaisho and
Akira 2006). MAPK activation by phosphorylation is regulated by MAPK kinase
(MKK). A direct known MKK for p38, JNK, and ERK is MKK3/6, MKK4/7, and
MEK1/2, respectively (Jeffrey, Rommel and Mackay et al. 2007). In short, TLR
signaling is transferred through MKK kinase to MKKs and finally to p38, JNK,
and ERK. Phosphorylation of these three MAPKs leads to the release of
2inflammatory cytokines such as TNF-α and IL-6 (Kawai and Akira 2006).
Inflammatory cytokines then trigger adjacent cells to produce chemokines or
adhesion molecules, thereby recruiting inflammatory cells such as macrophages to
the sites of infection. Sequentially, the macrophages engulf the invasive pathogens
and digest them by nitric oxide (NO) produced from inducible nitric oxide
synthase (iNOS), reactive oxygen species (ROS), or defensins (Flannagan, Cosio
and Grinstein 2009).
JAKs have four isoforms: JAK1, JAK2, JAK3, and Tyk2, while STATs have
seven isofroms: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and
STAT6. Specific combinations of JAK and STAT isoforms allow distinct cytokine
receptor signaling (Kisseleva et al. 2002). STAT1 and STAT3 have been shown
to be important in IL-10 production (Bouhamdan et al. 2015). Furthermore, IL-10,
fuctions as an anti-inflammatory cytokine, thus, inhibits the production of
proinflammatory cytokines such as TNFα and IL-6 in macrophages (Couper,
Blount and Riley et al. 2008).
In contrast to TLR4 stimulation, TLR2 stimulation is achieved by Pam3CSK4, a
synthetically made triacylated lipopeptide that imitates the acylated amino terminus
of bacterial lipopeptides, and LTA (Takeuchi, Akira et al. 1999). Compared to the
well-defined TLR4 downstream pathway, an overall view of TLR2 downstream
signaling requires further clarification. However, the converging point of TLR2 and
TLR4 downstream pathways: myeloid differentiation factor 88 (Myd88) has been
identified (Janssens and Beyaert 2002), shedding light to potential TLR2
downstream pathways as well as regulation mechanisms between TLR induced
transcription.
MyD88, a universal adapter protein for all TLR except TLR3, consists of a TIR
and death domain at its C- and N-terminal region, respectively (O’Neil and Bowie
2007). The TIR domain interacts with TLRs, while the death domain recruits IL-1
3receptor–associated kinase (IRAK) family members: IRAK-1, IRAK-2, IRAK-4,
and IRAK-M. IRAK-1 and IRAK-4 are known to play a critical role in the
MyD88-dependent pathway, signaling TRAF6 to trigger TGF-b–activated kinase
(TAK) 1 activation through ubiquitination and the canonical IkB kinases (IKK):
IKKα and IKKβ (Kaisho and Akira 2006). Sequentially, IKKs phosphorylate IkB
and initiate degradation leading to NF-kB downstream signaling (Kaisho and
Akira 2006). Moreover, TAK 1 activation can also lead to the activation of
MAPKs: p38, JNK, and ERK (Ninomiya-Tsuji1, Cao and Matsumoto et al. 1999).
Specifically, though the complete mechanism is unknown, TAK 1 activation signals
through Tumor progression locus 2 (TpL2), facilitating phosphorylation of MEK1/2
and subsequently, ERK (Arthur and Ley 2013). In brief, Myd88 dependent
signaling of TLR2 and TLR4 leads to MAPK or NF-kB activation, causing
transcription of inflammatory cytokine genes.
Furthermore, out of the five defined adaptors: MyD88, TIR-domain-containing
adapter-inducing interferon-β (TRIF), TRIF-related adaptor molecule (TRAM),
MyD88 adaptor-like (MAL), and sterile alpha motif and Armadillo motif
domain-containing protein (SARM) (Medzhitov et al. 1998; Kawai et al. 1999;
Fitzgerald et al. 2001; Horng et al. 2001, 2002; Kaisho et al. 2001; Yamamoto et al.
2003; O’Neil and Bowie 2007), the ones that bind to the intracellular domain of
TLR2 and TLR4 besides Myd88 are TRAM and TRIF (Nilsen et al. 2015). TLR4
is well known for utilizing the adaptors TRAM and TRIF, to activate the
interferon regulatory factor3 (IRF3) (Fitzgerald, Pitha and Golenbok 2003). In
comparison, recent studies confirm TRAM and TRIF involvement in TLR2
signaling regarding induction of CCL5, a chemokine that recruits leukocytes to
inflammation sites (Nilsen et al. 2015). Overall, much is yet to be discovered
concerning TLR2 downstream signaling.
Nonetheless, recent studies have provided the backbone for potential pathways in
4which TLR2 associates with MyD88, TRIF, or TRAM to trigger MAPK or NF-kB
activation, which in turn regulates the transcription of pro-inflammatory cytokine
genes, such as TNFα, IL-6, iNOS, Cox2, and IL1β (Nilsen et al. 2015; Arthur and
Ley 2013; Rayamajhi and Miao 2013). All in all, here I contribute to understanding
this overall structure by providing a novel contrasting transcription pattern of
pro-inflammatory cytokines in relation to LPS activated TLR4 and Pam3CSK4
activated TLR2.
52. Materials and Methods
2.1. Chemicals and antibodies
Pam3CSK4, LPS, LTA, Poly(I:C), and CpG DNA (ODN2006) were purchased
from Invivogen (San Diego, CA). p38 inhibitor (SB203580), JNK inhibitor
(AEG3482), and ERK inhibitor (U0126) were purchased from Calbiochem (San
Diego, CA). Phospho-specific antibodies against ERK1/2, p38, JNK, CREB, STAT1,
STAT3, as well as total CREB, iNOS, STAT1, and STAT3 are from Cell
Signaling Technology (Beverly, MA). Anti-rabbit IgG secondary antibody was also
purchased from Cell Signaling Technology. Anti-goat IgG secondary antibody,
phospho-specific antibody against IκBα, as well as total ERK1/2, Cox2, p38, and
β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). IL1β 
antibody was purchased from BioVision (San Francisco, CA).
2.2 Mice and isolation of bone marrow derived macrophages
6 to 12 week-old mice were dissected, and the bone marrow was flushed out.
Macrophages were cultured with DMEM media supplemented with 30% L929
supernatant containing macrophage-stimulating factor, glutamine, sodium pyruvate,
10% heat-inactivated Fetal Bovine Serum, and antibiotics for 7 days. BMDMs
were re-plated at a density of 1×10^6 cells/well in 12well plates the day before
the experiment.
62.3 Protein extraction and immunoblotting
After the appropriate treatments, cells were washed with cold Phosphate
Buffered Saline (PBS), and harvested in Radio-immunoprecipitation assay buffer
(RIPA) containing protease inhibitor and phosphatase inhibitor cocktails. Equal
amounts of proteins (20 μg) were mixed with the proper volume of 5X sample
buffer, separated on 10% or 12% SDS-polyacrylamide gel electrophoresis and
transferred to Nitrocellulose membrane at 50 V for 150-180 min. The NC
membrane was blocked with 5% dry milk in TBST (Tris-buffered saline with
0.1% Tween-20), rinsed, and incubated with primary antibody overnight. The blots
were washed and incubated with secondary anti-IgG antibody. Membranes were
washed and immuno-reactive bands were visualized using a chemiluminescent
substrate (ECL-Plus, GE Healthcare, Pittsburgh, PA).
2.4 Nitrite determination by Griess reaction
The nitrite concentration in the culture media was used as a measure of NO
production. After stimulation/incubation, the generation of NO in the cell culture
supernatant was determined by measuring nitrite accumulation in the medium
using Griess reagent(Sigma). 100μl of culture supernatant and 100μl of Griess
reagent were mixed and incubated for 5 min. The absorption was measured in an
automated plate reader at 540 nm. Sodium nitrite (NaNO2; Sigma) was used to
generate a standard curve for quantification. Background nitrite was subtracted
from the experimental values.
72.5 RNA extraction and quantitative reverse transcriptase/real-time PCR
Rinse cell monolayer with ice cold PBS once. Lyse cells directly in a culture
dish by adding 500μl of TRIZOL Reagent per well of 12well plate and pass the
cell lysate several times through a pipette. Add 100μl of chloroform and centrifuge
the samples at 13000rpm for 20 minutes at 4℃. Following centrifugation, the
mixture separates into lower red, phenol-chloroform phase, an interphase, and a
colorless upper aqueous phase containing RNA. Precipitate the RNA from the
aqueous phase by mixing with equal amount of isopropyl alcohol and
centrifuge(13000rpm, 20min, 4℃). Wash the RNA pellet once with 75% ethanol,
air-dry, then dissolve RNA in DEPC-treated water to create cDNA for qRT-PCR
analysis. Using Gapdh as a house-keeping gene control, CFX Connect Real-time
system (BioRad) was used to analyze mRNA level.
83. Results
3.1 ERK-dependent negative regulation of TLR2 induced response under
Pam3CSK4 challenge
3.1.1 ERK negatively regulates TLR2 induced secretion of iNOS and NO in
BMDMs.
Previous studies focused on LPS-induced TLR4 downstream signaling and its
relationship to ERK in BMDMs (Bouhamdan et al. 2015). In order to investigate
the credibility of previous observations and contrast it with the acquired results
regarding Pam3CSK4-induced TLR2 downstream signaling, I constructed the
following experiment. Since one of the main ways macrophages use to attack
pathogens is by nitric oxide production (Christian Bogdan et al. 2000), I first
focused on the production of NO in relation to iNOS (Fugen Akten 2004). I
cultured wild type BMDMs for a week and analyzed iNOS production in response
to LPS and Pam3CSK4 along with the presence and absence of U0126. BMDMs
were treated beforehand with U0126 (10 mM) for 30 min, and then LPS or
Pam3CSK4 was applied for 24 hours. iNOS was assessed using Western blotting
and nitric oxide in the conditioned media was measured using Griess assay. The
western blot (Figure 1B) showed drastic increase in Pam3CSK4-induced
expression of iNOS in the presence of U0126 compared to sole treatment of
Pam3CSK4, certifying negative regulation via ERK. Moreover, NO production level
was comparable in LPS-challenged BMDMs with or without U0126 (Figure 1A),
matching the results of previous studies (Bouhamdan et al. 2015) and illustrated
significant increase of NO release in Pam3CSK4+U0126 treated BMDMs in
comparison to BMDMs treated with only Pam3CSK4 (Figure 1A). In brief, the
9Western blot and Griess assay results validated that ERK negatively regulates
secretion of iNOS and NO by Pam3CSK4-triggered TLR2.
3.1.2 ERK negatively regulates TLR2 induced transcription and positively
regulates TLR4 induced transcription of TNFα, IL-6, Cox2, and IL1β.
Previous studies showed decrease of TNFα and IL-6 protein level using ELISA
when LPS challenged TLR4 downstream pathway was inhibited by U0126
(Bouhamdan et al. 2015). RT-PCR results displayed mRNA expression levels
relative to Gapdh (Figure 2) that were in agreement with the ELISA results of
previous studies (Bouhamdan et al. 2015). In other words, TNFα, IL-6, Cox2, and
IL1β exhibited decreased levels of mRNA expression when U0126 pre-treatment
inhibited the LPS-triggered TLR4 downstream pathway, proving ERK’s positive
regulation of TLR4 induced transcription. Furthermore, Pam3CSK4 activated TLR2
induced transcription of pro-inflammatory cytokines was upregulated when ERK
was blocked (Figure 2). Therefore, ERK negatively controls TLR2 induced
transcription under Pam3CSK4 challenge. Overall, ERK negatively regulates TLR2
induced transcription and positively regulates TLR4 induced transcription of
pro-inflammatory cytokines: TNFα, IL-6, Cox2, and IL1β.
3.2 Analysis of ERK-dependent regulation upon TLR downstream pathways
3.2.1 ERK-dependent negative regulation of Pam3CSK4-triggered TLR2
pathway does not signal via MEK1/2 and p-STAT.
In order to confirm the IL-10 regulation pathway through ERK and subsequent
STAT phosphorylation (Bouhamdan et al. 2015), I assessed phosphorylation of
STAT1, STAT3, and ERK in response to LPS. BMDMs were treated with LPS
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for different time points up to 8 hours to assess STAT1 (Tyr701) and STAT3
(Tyr705) phosphorylation. As in previous studies, BMDMs treated with or without
U0126 showed similar total STAT1 levels, and comparable STAT1 phosphorylation
in the case of U0126 treatment (Figure 3A). Likewise, BMDMs treated with U0126
responded to LPS challenge with similar STAT3 phosphorylation and comparable
total STAT3 levels (Figure 3A). It was possible that contrasting phosphorylation
patterns of STAT led to the contrasting transcription results by LPS and
Pam3CSK4. However, the assumption that Pam3CSK4 triggered TLR2 took the
same pathway of LPS was incorrect. The Western blot results exhibiting barely
induced p-STAT1 and p-STAT3 expression (Figure 3A) proved that Pam3CSK4
triggered TLR2 downstream signaling took a divergent path from LPS triggered
TLR4 downstream signaling.
3.2.2 ERK-dependent negative regulation of Pam3CSK4-triggered TLR2
pathway does not signal through phosphorylation of p38, JNK, IκBα, and
CREB.
Since Pam3CSK4-triggered TLR2 took a differing path from LPS-triggered
TLR4 downstream pathway, I tested several potential pathways regarding ERK
signaling such as: JNK, p38, CREB, and IκBα (Yoav D. Shaul, Rony Seger 2007).
In the Western blot results, p38, JNK, IκBα, and CREB showed similar levels of
phosphorylation up to 8 hours when applied with or without U0126 under
Pam3CSK4 challenge (Figure 3B). Moreover, phosphorylation patterns of p38, JNK,
IκBα, and CREB were also comparable under LPS challenge. Thus, ERK and
p-STAT are the dominant factors regulating the LPS-triggered TLR4 downstream
pathway. In brief, activation patterns of p38, JNK, IκBα, and CREB did not match
the contrasting patterns of transcription, leading to the need for further research of
potential factors that may be responsible for the two divergent pathways regarding
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Pam3CSK4 and LPS.
3.3 TLR2-specific regulation by ERK
3.3.1 Nitric oxide secretion and mRNA expression levels of TNFα, IL-6,
Cox2, and IL1β are negatively regulated by ERK in TLR2 specific manner
under Pam3CSK4 challenge.
Finally, I verified that the negative regulation mediated by ERK is TLR2
specific. I treated BMDMs with TLR2 specific ligands: Pam3CSK4 and LTA, and
contrasted NO level and mRNA expression level with ligands of TLR3 (Poly
(I:C)), TLR4 (LPS), and TLR9 (ODN2006) (Figure 4). Ligands of TLR3 and TLR9
resulted in minimal expression of NO (Figure 4A) and basal mRNA expression of
TNFα, IL-6, Cox2, and IL1β (Figure 4B). Therefore, these results collectively
indicate that the hypothesis: ERK specifically targets and negatively regulates
TLR2-induced transcription of TNFα, IL-6, iNOS, Cox2, and IL1β under
Pam3CSK4 challenge is most likely true. However, additional experimentation of
various ligands of the TLR ligand family is needed to strengthen the hypothesis.
Moreover, further research is required to clarify the exact reason for LTA
resulting in comparably low levels of nitric oxide and mRNA expression of
pro-inflammatory cytokines. Overall, ERK dependent negative regulation of NO
secretion and mRNA expression of pro-inflammatory cytokines: TNFα, IL-6, Cox2,
and IL1β is a unique phenomenon restricted to TLR2 triggered by Pam3CSK4.
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4. Discussion
TLR has been acknowledged as a key factor linked to the prevention and
treatment of cancer and inflammatory diseases: rheumatoid arthritis, inflammatory
bowel disease, and systemic lupus erythematosus (Stefan K. Drexler, Brian M.
Foxwell 2010). Moreover, inhibitors of TLR2, TLR4, TLR7, and TLR9 are being
selected for preclinical and clinical trials (Elizabeth J. Hennessy, Andrew E. Parker
and Luke A. J. O'Neill 2010). Thus, here, I provide additional insight into the TLR
downstream signaling pathway which is crucial in the capability of regulating
TLR activity without triggering unwanted side effects.
LPS triggers TLR4 to pass on signaling to Myd88 and TRIF (Akira S., Takeda
K. 2004). Moreover, it has been shown that LPS-induced expression of iNOS in
macrophages is positively regulated by Src-family tyrosine kinases via the
TRIF-dependent signaling pathways of TLR4 (Hwang DH et al. 2005). Thus,
ERK dependent regulation of iNOS can be determined only when TRIF knockout
mice is available. Nevertheless, it is clear that Pam3CSK4-induced expression of
iNOS is negatively regulated via ERK since, the western blot (Figure 1B) shows
drastic increase in iNOS when comparing the Pam3CSK4 and Pam3CSK4+ERK
inhibitor (U0126) lanes. iNOS mRNA RT results showed minimum reading at the
24hr time point (data not shown). It is likely that iNOS mRNA fluctuated between
the 24hr time point and requires additional time-frame based collection of
Pam3CSK4+U0126 mRNA samples to visualize the increase of iNOS mRNA
expression leading to the confirmed increase in the secretion of iNOS.
Furthermore, NO level does not seem to have significant difference in LPS and
LPS+U0126 samples (Figure 1A). This is most likely due to LPS signaling via
TRIF affecting iNOS signaling, therefore, also needs TRIF knockout mice for
13
confirmation.
In comparison with iNOS, the mRNA levels of TNFα, IL-6, Cox2, and IL1β 
show obvious contrasting results between LPS and Pam3CSK4 (Figure 2). In brief,
LPS+U0126 mRNA levels of the four pro-inflammatory cytokines: TNFα, IL-6,
Cox2, and IL1β indicate decreased expression compared to mRNA levels of
samples applied with only LPS, which are in agreement with results provided in
previous studies (Bouhamdan et al. 2015). While, Pam3CSK4+U0126 mRNA levels
of the cytokines reveal increased expression as to mRNA levels of samples applied
solely with Pam3CSK4.
The way that Pam3CSK4 shows contrasting cytokine level patterns to LPS is
likely by signaling through different transcription factors rather than STAT.
Considering previous studies that validate phosphorylation variations of STAT is
the signaling mechanism downstream of LPS triggered TLR4 and ERK
(Bouhamdan et al. 2015), and the fact that Pam3CSK4 barely induced any
p-STAT expression (Figure 3A), I tested several potential pathways regarding
ERK signaling such as: JNK, p38, CREB, and IκBα (Yoav D. Shaul, Rony Seger
2007) to confirm the hypothesis above. None of them showed significant difference
in the level of phosphorylation when applied with U0126 (Figure 3B). Further
investigation is required to find the factor responsible for the differing
transcription patterns of pro-inflammatory cytokines induced by LPS and
Pam3CSK4 under ERK-dependent regulation.
Due to the lack of Mek1(d/d) Sox2 (Cre/+) mice (Bouhamdan et al. 2015) for in
vivo experimentation, I attempted to create a MEK1/2 deficient cell line using the
CRISPR-CAS9 system on macrophage-like cell lines: J774A.1, Raw264.7, and
iBMDM. However, none of the cell lines showed increased mRNA expression level
or nitric oxide secretion when comparing treatment with both Pam3CSK4 and
U0126 to sole treatment of Pam3CSK4 (data not shown). Therefore, it is necessary
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to acquire Mek1/2 deficient mice for in vivo experimentation.
In final, I attempted to certify that the ERK-dependent negative regulation of
cytokine mRNA level expression and NO secretion is TLR2 specific. Griess assay
and RT-PCR results verified that Pam3CSK4 induced TLR2 specific responses via
ERK (Figure 4). However, LTA showed basal level of expression. The fact that
LTA-induced expression of genes are substantially delayed compared to other
TLR2 ligands (Elizabeth M. Long et al. 2009) and that a murine model of acute
inflammation showed Pam3CSK4’s capability to stimulate robust leukocyte
recruitment in vivo, while LTA remained functionally inert (Elizabeth M. Long et
al. 2009), explains the basal mRNA and NO readings when BMDMs were treated
with LTA and collected at the 24hr time point. In short, the underlying reasons
for basal readings regarding LTA may be due to the prolonged period required for
LTA stimulation or an unknown mechanism in which LTA fails to initiate
inflammatory responses.
Overall, I acquired a partial structure of the pathway (Figure 5) resulting in the
contrasting transcription patterns of pro-inflammatory cytokines due to
LPS-induced TLR4 signaling and Pam3CSK4-induced TLR2 signaling. This
structure provides insight into the regulation mechanisms of TLR downstream
signaling. All in all, this paper provides further comprehension in the designing of
drugs regulating TLR activity, which is connected to inflammatory diseases and
cancer.
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Fig.1 Pam3CSK4 activated ERK negatively regulates iNOS and nitric oxide
production. BMDMs derived from WT mice were treated with LPS(100ug/mL)
and Pam3CSK4(1mg/mL) for 24 h, along with p38 inhibitor(SB203580), JNK
inhibitor(AEG3482), or ERK inhibitor(U0126) at a concentration of 10mM. (A) The
nitrite concentration in the culture medium was used as a measure of NO
production. After stimulation/incubation, the generation of NO in the cell culture
supernatants was determined by measuring nitrite accumulation in the medium
using Griess reaction. Data are presented as mean of three independent
experiments. Using unpaired t-test, a p value<0.05 was considered significant and
error bars indicate SD. (B) Whole cell extracts were prepared and 20 μg total
protein was subjected to SDS-PAGE and Western blot analysis using antibodies
for iNOS, Cox2, and IL1β. Equal loading was confirmed by total β-actin antibody.
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Fig.2 ERK-dependent negative regulation of pro-inflammatory cytokines in
response to Pam3CSK4. BMDMs derived from WT mice were treated with
LPS(100ug/mL) and Pam3CSK4(1mg/mL) for 24 h, along with p38
inhibitor(SB203580), JNK inhibitor(AEG3482), or ERK inhibitor(U0126) at a
concentration of 10mM. Using Gapdh as a house-keeping gene control, CFX
Connect Real-time system (BioRad) was used to analyze mRNA level. Data are
presented as mean of three independent experiments. Using unpaired t-test, a p
value<0.05 was considered significant and error bars indicate SD.
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Fig.3 Pam3CSK4 via ERK pathway does not involve p-STAT, p-p38,
p-JNK, p-CREB, and p-IκBα. Whole cell extracts were prepared and 20 μg total
protein was subjected to Western blot analysis. (A) Phospho-specific antibodies
for STAT1 (Tyr701), STAT3 (Tyr705), and ERK (Thr202/Tyr204) were used.
Equal loading was confirmed by total STAT1, STAT3, and β-actin antibody. (B)
Detection of phospho-specific antibodies for p38 (Thr180/Tyr182), JNK
(Thr183/Tyr185), CREB (Ser133), IκBα (Ser32), and ERK (Thr202/Tyr204) in
response to Pam3CSK4 and LPS treatment for different time points are shown.
Equal loading was determined using antibodies against total p38, CREB, and ERK.
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Fig. 4 ERK-dependent negative regulation of nitric oxide and
pro-inflammatory cytokines are TLR2 specific under Pam3CSK4 challenge.
BMDMs derived from WT mice were treated with LPS(100ug/mL) and
Pam3CSK4(1mg/mL) for 24 h, along with p38 inhibitor(SB203580), JNK
inhibitor(AEG3482), or ERK inhibitor(U0126) at a concentration of 10mM. (A) The
nitrite concentration in the culture medium was used as a measure of NO
production. After stimulation/incubation, the generation of NO in the cell culture
supernatants was determined by measuring nitrite accumulation in the medium
using Griess reaction. Data are presented as mean of three independent
experiments. Using unpaired t-test, a p value<0.05 was considered significant and
error bars indicate SD. (B) Using Gapdh as a house-keeping gene control, CFX
Connect Real-time system (BioRad) was used to analyze mRNA level. Data are
presented as mean of three independent experiments. Using unpaired t-test, a p
value<0.05 was considered significant and error bars indicate SD.
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Fig. 5 Schematic of LPS and Pam3CSK4 stimulated pathways leading to the
contrasting patterns of ERK-dependent regulation.
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Gene Primer sequence
TNF-alpha q1F ATGTCCATTCCTGAGTTCTG
TNF-alpha q1R AATCTGGAAAGGTCTGAAGG
IL-1 beta q1F TCAACCAACAAGTGATATTCTC
IL-1 beta q1R ACACAGGACAGGTATAGATTC
IL-6 q1F CCAAGACCATCCAATTCATC
IL-6 q1R CCACAAACTGATATGCTTAGG
Ptgs2(Cox2) q1F GCCCGTGCTGCTCTGTCTTAAC
Ptgs2(Cox2) q1R GTTGCTCTAGGCTTTGCTGGCTAC
Gapdh_F GGCAAATTCAACGGCACAGTCAAG
Gapdh_R TCGCTCCTGGAAGATGGTGATGG
iNOS_F AATCTTGGAGCGAGTTGTGG
iNOS_R CAGGAAGTAGGTGAGGGCTTG
Table 1. Forward and reverse primers used for RT-PCR
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Abstract in Korean
쥐 골수세포에서 ERK의 TLR2 관련 cytokine인 TNFa, IL-6,
iNOS, Cox2, IL1β에 대한 음성조절 기작
ERK는 mitogen-activated protein kinase의 한 종류로 TLR activation과 이와 관련
된 cytokine production에 중요 역할을 하는 것으로 밝혀졌다. 위와 같은 사실을 기재
한 논문은 LPS에 의한 TLR4 induced transcription과 ERK사이의 상관관계에 초점을
맞췄으나, 이 논문은 ERK와 Pam3CSK4로 인한 TLR2 induced transcription 사이의
관계를 규명하고자 한다. 더 나아가, 기존 논문에 기록된 결과들을 재확인하고, TNFa,
IL-6, iNOS, Cox2, IL1β와 같은 pro-inflammatory cytokine들의 변화가 ERK
dependent한지 여부와 TLR2 downstream을 ERK가 negatively regulate하는 pathway
를 확인하는 것이 최종 목적이다. ERK dependency를 확인하기 위해서는 ERK에 대
한 검증된 inhibitor가 없는 관계로, ERK를 직접적으로 regulate하는 것으로 알려진
upstream factor인 MEK에 대한 inhibitor를 이용하여 실험을 setting한 후, 각각의
cytokine에 대해 Western Blotting을 통한 protein level과 RT-PCR을 통한 mRNA
level 변화 경향성에 대한 자료를 얻었다. 더 나아가 ERK가 TLR2 downstream을 조
절하는 지점을 찾기 위해 기존 논문에서 명시한 MEK1/2와 p-STAT 관련 기작은 물
론, 가능성 있는 p38, JNK, IκBα, CREB의 인산화 변화 정도를 Western Blotting을
이용하여 확인하였다. 추가적으로 in vivo 실험을 위하여 macrophage-like cell line들
을 testing하여 MEK1/2에 대한 KO cell line을 얻으려고 시도하였다. 마지막으로
TLR2 specific한 ligand인 Pam3CSK4를 통해 얻은 결과가 TLR3, TLR4, TLR9에서
는 일어나는지 않을 것이라는 가설을 검증하였다. 종합하자면, 위의 자료들은 ERK의
TLR2 관련 pro-inflammatory cytokine들에 대한 음성조절 기작을 규명함으로써 TLR
관련 기작을 조절하여 염증성 질환과 암을 치료하는 약을 제조하는데 도움을 줄 수
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있을 것이다.
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